Epigenetic silencing of 14-3-3sigma in cancer.

[1]  M.-H. Lee,et al.  Negative cell cycle regulator 14-3-3σ stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt , 2006, Oncogene.

[2]  A. Karami,et al.  Fibroblast extracellular matrix gene expression in response to keratinocyte‐releasable stratifin , 2006, Journal of cellular biochemistry.

[3]  Lü-sheng Si.  [Cancer epigenetics]. , 2006, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[4]  R. Zhao,et al.  DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer. , 2006, Cancer research.

[5]  Baoguang Han,et al.  Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. , 2006, Cancer research.

[6]  R. Rosell,et al.  14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  I. Verma,et al.  Identification of 14-3-3sigma mutation causing cutaneous abnormality in repeated-epilation mutant mouse. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Niemantsverdriet,et al.  Radiation response and cell cycle regulation of p53 rescued malignant keratinocytes. , 2005, Experimental cell research.

[9]  A. Valent,et al.  P73 functionally replaces p53 in Adriamycin‐treated, p53‐deficient breast cancer cells , 2005, International journal of cancer.

[10]  L. Siracusa,et al.  A mutation in stratifin is responsible for the repeated epilation (Er) phenotype in mice , 2005, Nature Genetics.

[11]  R. Jaenisch,et al.  Global loss of imprinting leads to widespread tumorigenesis in adult mice. , 2005, Cancer cell.

[12]  G. Tonini,et al.  Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors , 2005, Oncogene.

[13]  Antonio Porro,et al.  In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Barbacid,et al.  Tumour biology: Senescence in premalignant tumours , 2005, Nature.

[15]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[16]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[17]  W. Deppert,et al.  A Novel Human p53 Isoform Is an Essential Element of the ATR-Intra-S Phase Checkpoint , 2005, Cell.

[18]  Qing‐Yu He,et al.  Comparative proteomic analysis of esophageal squamous cell carcinoma , 2005, Proteomics.

[19]  S. Natsugoe,et al.  Predictive value of p53 and 14‐3‐3σ for the effect of chemoradiation therapy on esophageal squamous cell carcinoma , 2005, Journal of surgical oncology.

[20]  Joachim Diebold,et al.  Functional epigenomics identifies genes frequently silenced in prostate cancer. , 2005, Cancer research.

[21]  M. Yaffe,et al.  A Structural Basis for 14-3-3σ Functional Specificity*♦ , 2005, Journal of Biological Chemistry.

[22]  A. Ghahary,et al.  Stratifin-induced matrix metalloproteinase-1 in fibroblast is mediated by c-fos and p38 mitogen-activated protein kinase activation. , 2005, The Journal of investigative dermatology.

[23]  M. Day,et al.  Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway. , 2005, Cancer research.

[24]  R. Margreiter,et al.  14-3-3σ Expression Is an Independent Prognostic Parameter for Poor Survival in Colorectal Carcinoma Patients , 2005, Clinical Cancer Research.

[25]  J. Cameron,et al.  Expression and prognostic significance of 14-3-3 sigma and ERM family protein expression in periampullary neoplasms , 2005, Cancer biology & therapy.

[26]  A. Carvalho,et al.  Frequent 14-3-3σ promoter methylation in benign and malignant prostate lesions , 2005 .

[27]  J. Celis,et al.  Down-regulation of the Tumor Suppressor Protein 14-3-3σ Is a Sporadic Event in Cancer of the Breast , 2005, Molecular & Cellular Proteomics.

[28]  H. Hermeking,et al.  The crystal structure of the non-liganded 14-3-3σ protein: insights into determinants of isoform specific ligand binding and dimerization , 2005, Cell Research.

[29]  H. Hermeking,et al.  Downregulation of 14-3-3σ in ovary, prostate and endometrial carcinomas is associated with CpG island methylation , 2005, Modern Pathology.

[30]  H. Denk,et al.  Metaplastic Breast Carcinomas: Are They of Myoepithelial Differentiation?: Immunohistochemical Profile of the Sarcomatoid Subtype Using Novel Myoepithelial Markers , 2005, The American journal of surgical pathology.

[31]  T. Nakajima,et al.  Large cell neuroendocrine carcinoma of the lung: a comparison with large cell carcinoma with neuroendocrine morphology and small cell carcinoma. , 2005, Lung cancer.

[32]  F. Herrmann,et al.  Immunohistochemical expression of 14‐3‐3 sigma protein in human urological and gynecological tumors using a multi‐tumor microarray analysis , 2005, Pathology international.

[33]  T. Kouzarides,et al.  Myc represses transcription through recruitment of DNA methyltransferase corepressor , 2005, The EMBO journal.

[34]  P. Hainaut,et al.  The expression of TA and ΔNp63 are regulated by different mechanisms in liver cells , 2005, Oncogene.

[35]  H. Hermeking,et al.  Prostate cancer is characterized by epigenetic silencing of 14-3-3σ expression , 2004, Oncogene.

[36]  Y. Mohri,et al.  The clinical implication of 14-3-3 sigma expression in primary gastrointestinal malignancy. , 2004, International journal of oncology.

[37]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[38]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[39]  T. Nakajima,et al.  Immunohistochemical expression of 14‐3‐3 sigma protein in various histological subtypes of uterine cervical cancers , 2004, Pathology international.

[40]  S. Plymate,et al.  Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12 , 2004, Oncogene.

[41]  H. Friess,et al.  Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. , 2004, Carcinogenesis.

[42]  D. Görlich,et al.  Exportin 7 defines a novel general nuclear export pathway , 2004, The EMBO journal.

[43]  Zhongmin Guo,et al.  RACK1 and Stratifin Target ΔNp63α for a Proteasome Degradation in Head and Neck Squamous Cell Carcinoma Cells upon DNA Damage , 2004 .

[44]  T. Nakajima,et al.  Immunohistochemical analysis of 14‐3‐3 sigma and related proteins in hyperplastic and neoplastic breast lesions, with particular reference to early carcinogenesis , 2004, Pathology international.

[45]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[46]  K. Horie-Inoue,et al.  14-3-3σ is down-regulated in human prostate cancer , 2004 .

[47]  M. Weinfeld,et al.  Keratinocyte-releasable stratifin functions as a potent collagenase-stimulating factor in fibroblasts. , 2004, The Journal of investigative dermatology.

[48]  Lang Li,et al.  Loss of 14-3-3σ in Prostate Cancer and Its Precursors , 2004, Clinical Cancer Research.

[49]  R. Dahiya,et al.  Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. , 2004, Biochemical and biophysical research communications.

[50]  S. Inoue,et al.  Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  T. Nakajima,et al.  Inactivation of 14-3-3sigma by hypermethylation is a rare event in colorectal cancers and its expression may correlate with cell cycle maintenance at the invasion front. , 2004, Cancer letters.

[52]  J. Celis,et al.  Expression of the Tumor Suppressor Protein 14-3-3σ Is Down-regulated in Invasive Transitional Cell Carcinomas of the Urinary Bladder Undergoing Epithelial-to-Mesenchymal Transition* , 2004, Molecular & Cellular Proteomics.

[53]  S. Lakhani,et al.  Distribution and significance of 14‐3‐3σ, a novel myoepithelial marker, in normal, benign, and malignant breast tissue , 2004, The Journal of pathology.

[54]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[55]  H. Hermeking,et al.  Analysis of 14-3-3σ expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma , 2003, Oncogene.

[56]  Jesse D. Martinez,et al.  Reduction of 14-3-3 Proteins Correlates with Increased Sensitivity to Killing of Human Lung Cancer Cells by Ionizing Radiation , 2003, Radiation research.

[57]  C. Iacobuzio-Donahue,et al.  Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. , 2003, Cancer research.

[58]  A. Bird,et al.  Deficiency of Mbd2 suppresses intestinal tumorigenesis , 2003, Nature Genetics.

[59]  Rork Kuick,et al.  Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. , 2003, Cancer research.

[60]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[61]  R. Jaenisch,et al.  Induction of Tumors in Mice by Genomic Hypomethylation , 2003, Science.

[62]  Christine A Iacobuzio-Donahue,et al.  Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. , 2003, The American journal of pathology.

[63]  J. Pietenpol,et al.  The ΔNp63α Phosphoprotein Binds the p21 and 14-3-3σ Promoters In Vivo and Has Transcriptional Repressor Activity That Is Reduced by Hay-Wells Syndrome-Derived Mutations , 2003, Molecular and Cellular Biology.

[64]  R. Stahel,et al.  Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation , 2003, Cell Death and Differentiation.

[65]  J. Herman,et al.  A systematic profile of DNA methylation in human cancer cell lines. , 2003, Cancer research.

[66]  A. Bird,et al.  Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals , 2003, Nature Genetics.

[67]  K. Bhatia,et al.  Short Communication The Tumor Suppressor Gene 14-3-3 Is Commonly Methylated in Normal and Malignant Lymphoid Cells , 2003 .

[68]  Y. Yatabe,et al.  Decreased expression of 14-3-3σ in neuroendocrine tumors is independent of origin and malignant potential , 2002, Oncogene.

[69]  J. Hicks,et al.  Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. , 2002, Cancer research.

[70]  Hwoong-Yong Jung,et al.  Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. , 2002, The American journal of pathology.

[71]  E. Li.  Chromatin modification and epigenetic reprogramming in mammalian development , 2002, Nature Reviews Genetics.

[72]  Tomoki Tokugawa,et al.  Modes of silencing of p16 in development of esophageal squamous cell carcinoma. , 2002, Cancer research.

[73]  K. Robertson.  DNA methylation and chromatin – unraveling the tangled web , 2002, Oncogene.

[74]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[75]  Bert Vogelstein,et al.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells , 2002, Nature.

[76]  J. P. Jackson,et al.  Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase , 2002, Nature.

[77]  Y. Yatabe,et al.  Frequent and histological type-specific inactivation of 14-3-3σ in human lung cancers , 2002, Oncogene.

[78]  W. Kuo,et al.  Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. , 2002, Cancer research.

[79]  B. Gusterson,et al.  Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. , 2002, Cancer research.

[80]  A. Petrenko,et al.  Methylation and silencing of the retinoic acid receptor-β2 gene in cervical cancer , 2002, BMC Cancer.

[81]  B. Gusterson,et al.  Coincident inactivation of 14-3-3σ and p16INK4a is an early event in vulval squamous neoplasia , 2002, Oncogene.

[82]  P. Laird,et al.  Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice. , 2002, Cancer research.

[83]  B. Verdoodt,et al.  The G2/M Regulator 14-3-3ς Prevents Apoptosis through Sequestration of Bax* , 2001, The Journal of Biological Chemistry.

[84]  E. Selker,et al.  A histone H3 methyltransferase controls DNA methylation in Neurospora crassa , 2001, Nature.

[85]  M. Matzke,et al.  RNA: Guiding Gene Silencing , 2001, Science.

[86]  J. Bender.  A Vicious Cycle RNA Silencing and DNA Methylation in Plants , 2001, Cell.

[87]  S. Sukumar,et al.  Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer , 2001, Oncogene.

[88]  E. Liu,et al.  BRCA1 Is a Selective Co-activator of 14-3-3ς Gene Transcription in Mouse Embryonic Stem Cells* 210 , 2001, The Journal of Biological Chemistry.

[89]  D. Ponzin,et al.  p63 identifies keratinocyte stem cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[90]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[91]  Hiromu Suzuki,et al.  Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 σ gene in human hepatocellular carcinoma , 2000, Oncogene.

[92]  M. Hande,et al.  Inactivation of 14-3-3ς Influences Telomere Behavior and Ionizing Radiation-Induced Chromosomal Instability , 2000, Molecular and Cellular Biology.

[93]  M. Toyota,et al.  Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers. , 2000, Cancer research.

[94]  Mong-Hong Lee,et al.  Association of the Cyclin-dependent Kinases and 14-3-3 Sigma Negatively Regulates Cell Cycle Progression* , 2000, The Journal of Biological Chemistry.

[95]  K. Kinzler,et al.  Cooperative effects of genes controlling the G(2)/M checkpoint. , 2000, Genes & development.

[96]  E. Dellambra,et al.  Downregulation of 14-3-3σ Prevents Clonal Evolution and Leads to Immortalization of Primary Human Keratinocytes , 2000, The Journal of cell biology.

[97]  T. Pandita,et al.  High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[98]  K. Robertson,et al.  Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. , 2000, Nucleic acids research.

[99]  G. Landes,et al.  Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. , 1999, Cancer research.

[100]  K. Kinzler,et al.  14-3-3σ is required to prevent mitotic catastrophe after DNA damage , 1999, Nature.

[101]  A. Marzo,et al.  Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. , 1999, Cancer research.

[102]  T. Curran,et al.  Role of DNA 5-methylcytosine transferase in cell transformation by fos. , 1999, Science.

[103]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[104]  A. Bird,et al.  Number of CpG islands and genes in human and mouse. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[105]  J. Guénet,et al.  Multiple cutaneous papillomas and carcinomas that develop spontaneously in a mouse mutant, the repeated epilation heterozygote Er/+. , 1985, Journal of the National Cancer Institute.

[106]  A. Feinberg,et al.  Hypomethylation distinguishes genes of some human cancers from their normal counterparts , 1983, Nature.

[107]  A. Carvalho,et al.  Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. , 2005, DNA and cell biology.

[108]  M. Weinfeld,et al.  Differentiated keratinocyte-releasable stratifin (14-3-3 sigma) stimulates MMP-1 expression in dermal fibroblasts. , 2005, The Journal of investigative dermatology.

[109]  S. Inoue,et al.  14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[110]  P. Laird.  Cancer epigenetics. , 2005, Human molecular genetics.

[111]  David I. K. Martin,et al.  Germline epimutation of MLH1 in individuals with multiple cancers , 2004, Nature Genetics.

[112]  K. Horie-Inoue,et al.  14-3-3sigma is down-regulated in human prostate cancer. , 2004, Biochemical and biophysical research communications.

[113]  Zhongmin Guo,et al.  RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. , 2004, Cell cycle.

[114]  H. Hermeking,et al.  Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression. , 2004, Oncogene.

[115]  Lang Li,et al.  Loss of 14-3-3sigma in prostate cancer and its precursors. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[116]  J. Pietenpol,et al.  The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. , 2003, Molecular and cellular biology.

[117]  K. Bhatia,et al.  The tumor suppressor gene 14-3-3 sigma is commonly methylated in normal and malignant lymphoid cells. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[118]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[119]  E. Liu,et al.  BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells. , 2001, The Journal of biological chemistry.

[120]  S. Sukumar,et al.  Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. , 2001, Oncogene.

[121]  B. Verdoodt,et al.  The G2/M regulator 14-3-3sigma prevents apoptosis through sequestration of Bax. , 2001, The Journal of biological chemistry.

[122]  K. Kinzler,et al.  14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. , 1999, Nature.

[123]  K. Kinzler,et al.  14-3-3sigma is a p53-regulated inhibitor of G2/M progression. , 1997, Molecular cell.